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Abstract: An orthodontist attends the scientific orthodontic congress and passing by the company exhibi-
tions receives a free sample of a novel orthodontic archwire introduced in the market for initial alignmen-
t/levelling with favourable performance over conventional superelastic nickel-titanium archwires. This
novel archwire should increase according to the manufacturer’s claims alignment efficacy and halve the
pain for the patient. After using the free sample wire on a patient and observing that the patient felt
little to no pain during the alignment/levelling phase, the orthodontist decides to venture into unknown
territory and find out if this holds true for most of her patients by doing a randomised clinical trial in
her practice.
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Theoretical scenario 
An orthodontist attends the scientific orthodontic congress and passing by the company exhibitions receives 
a free sample of a novel orthodontic archwire introduced in the market for initial alignment/levelling with 
favourable performance over conventional superelastic nickel-titanium archwires. This novel archwire 
should increase according to the manufacturer’s claims alignment efficacy and halve the pain for the patient. 
After using the free sample wire on a patient and observing that the patient felt little to no pain during the 
alignment/levelling phase, the orthodontist decides to venture into unknown territory and find out if this holds 
true for most of her patients by doing a randomised clinical trial in her practice. 
 She opts for the simplest trial design possible and plans to do a parallel randomised trial with two 
groups: one receiving the novel (hereon ‘experimental’) archwire and the other receiving a conventional 
superelastic nickel-titanium (hereon ‘control’) archwire. She plans to assess patient-reported pain at its peak 
24 hours after insertion of the first archwire using a Visual Analogue Scale (VAS) with a 100-mm horizontal 
line. Patients mark felt pain intensity between ‘no pain’ on the its left side and ‘worst pain possible’ on the 
right side; this is a valid and reliable tool for pain assessment. She also performs an a priori sample size 
calculation to decide how many patients she would need to recruit for her trial to be adequately powered to 
identify an existing difference in pain between the experimental and control archwire, if such a difference 
really does exist. The sample size calculation is based on an expected pain for the control archwire of 28.8 
mm in VAS (standard deviation of 11.0 mm in VAS) according to a previous study (Sandhu and Sandhu, 
2013) the author judged to be of similar setting and conduct with her own. Expecting to find, according to 
the manufacturer’s claims, a 50% reduction in pain using a t-test for independent samples, she sets α (type 
I “false positive” error) at 5% and power (1 minus β [type II “false negative” error]) at 80%, as is many times 
done (MacFarlane, 2003). This calculation gives her a total sample of 22 patients needed (11 in each group), 
to which she adds another 15% to account for possible losses to follow-up and ends up recruiting 26 patients 
in total (13 in each group). 
After collecting and analysing the trial’s data, she finds to her astonishment no statistically significant 
or clinically relevant difference in pain during leveling and aligning between the two archwires (mean 
difference of 17%; P>0.05). 
 
Which of the following statements are true, if any? 
(A) As the trial included a sample size calculation and found no significant difference, we can be confident 
that no difference exists between the two archwire in reality.  
(B) The sample size calculation that was performed ensures that this trial is adequately powered to identify 
any existing difference between the two archwires. 
(C) Being too optimistic during sample size calculation can lead to a trial being underpowered to detect a 
clinically relevant effect.  
(D) It is always prudent to include as many patients as possible in a clinical trial.  
 
Discussion 
Sample size calculations are based on several a priori assumptions made by the researcher, as has been 
previously shown (MacFarlane 2003; Pandis and Cobourne, 2015). These include among others the 
anticipated mean response in the control and the experimental groups and their standard deviations, which 
are needed to calculate the minimal clinically important difference (MCID) to be detected from the trial. As 
the name implies, this is the smallest treatment effect (i.e. difference between the two groups) that the trial 
should be able to identify, if such an effect really exists. This does not mean necessarily that a treatment 
effect (i.e. difference between the two groups) exists. Only that if such a treatment exists and is equal or 
larger than the MCID that an adequately powered trial has good chances to find this. So statement (A) is 
wrong. 
Clinical trials should then have enough power to identify existing differences between groups being 
same or larger than the MCID, but they would probably be underpowered to identify an existing difference 
that is smaller than the MCID. Therefore, it is imperative that careful consideration is given in determining 
the expected MCID of a treatment and this has to be based on both clinical and statistical grounds. For one, 
an MCID should be large enough to affect clinical practice or the whole point of making a clinical trial 
becomes void. Additionally, MCIDs should be realistic enough, which means that they should correspond 
to the intervention’s clinical performance that can be expected according the intervention’s technical and 
biological characteristics. Insight on the expected average performance of a new treatment can also be 
gleamed by looking at the observed effects of similar interventions in other trials. Setting an overly optimistic 
or overly pessimistic MCID – be it intentional or not – can have dire consequences for the feasibility, 
duration, costs, and scientific value of a clinical trial, as it influences the results of the sample size 
calculation. 
This can be seen in Table 1, where sample size calculations for a series of different MCIDs are 
given, while the anticipated mean pain response in the control group is kept the same. Differences in pain 
between the two groups are given both in terms of relative reduction in mm on the VAS scale 
(unstandardized effect size) and as Cohen’s d (Cohen, 1969). Cohen’s d is a standardised effect size, which 
is simply the difference between the two means divided by their pooled standard deviation and has no 
measurement units. This has the advantage that it can be used across different outcomes or disciplines to 
compare the magnitude of an effect, while at the same time having the disadvantage of not being clinically 
intuitive. Cohen introduced arbitrary cut-offs for the interpretation of d of such as small (d=0.2), medium 
(d=0.5) and large (d=0.8), but at the same time urged for strong caution that "this is an operation fraught 
with many dangers". The Cohen’s d is used in this scenario to illustrate in simple terms the difference in 
magnitude and the impact it can have on sample size calculations. The original trial presented in the 
theoretical scenario set adopted a relative reduction of 50% or a very large Cohen’s d of 1.3 (i.e. a difference 
of 1.3 times the standard deviation) and resulted in a needed sample of 22 patients. One can see that as 
the MCID becomes smaller the needed sample to keep the same power increases drastically: the needed 
sample for a large, medium, or small effect according to Cohen would be 52 patients (d=0.8), 128 patients 
(d=0.5), and 352 patients (d=0.3) (pink dotted line in Figure 1). 
 
Table 1. Results of sample size calculations to identify an existing difference in pain 24 hours after archwire 












A 28.8 mm 14.4 mm -50% 1.3 22 
B Same 17.7 mm -39% 1.0 34 
C Same 20.0 mm -31% 0.8 52 
D Same 23.3 mm -19% 0.5 128 
E Same 25.5 mm -11% 0.3 352 
* the control group mean and standard deviation were taken from the previous trial of Sandhu and Sandhu 
(2013). We assume that the control and experimental group would have the same standard deviation. 
 
**Both Table 1 and Figure 1 should be put, if possible, on the second or third page of the type-setted paper** 
 
Being too optimistic at the trial’s start and expecting that a very large MCID of d=1.3 – while much smaller 
differences of d between 0.3-0.5 are found in reality – results in clinical trial with a very small sample. This 
means that the present trial might be severely underpowered to detect an existing difference in pain that is 
less than 50% and statement (B) is wrong. Such differences 31% (d=0.8) or even 19% (d=0.5) might still be 
clinically relevant to the patient or the orthodontist, especially if the novel archwire comes with little to no 
extra costs or adverse effects compared to the conventional archwire. The current trial would have only 43% 
power to detect a d=0.8 and 20% power to detect a d=0.5. Or expressed as type II errors (β), the current 
trial has a 57% or 80% chance to miss identifying a clinically relevant effect that might exist. Therefore, it 
might well be that a difference in the pain response between the two archwire exists, but this trial could not 
find it, and statement (C) is correct. 
Notwithstanding this, being too pessimistic of an expected treatment effect and setting a very small 
MCID of d=0.3 would lead the orthodontist to recruit at least 352 patients in total to identify a 11% reduction 
in felt pain. Given the negligible difference of 3.3 mm in VAS that this translates to, the pain’s short duration, 
and the available safe methods to alleviate pain during fixed appliance treatment it would seem neither 
prudent nor easily ethically justifiable to perform such a trial. Such small trials might be meaningful in settings 
were the long-term survival of critically-ill patients can be increased by simple measures but would probably 
be regarded as research waste in the current setting. Assumptions about sample size calculation should 
ideally meet a fine balance among clinically relevant gains, careful management of research resources, and 
avoidance of unnecessarily putting patients in a clinical trial environment. Statement (C), which implies that 
when it comes to sample size more is always better is therefore not true. 
Therefore, the mere fact that a sample size calculation has been performed does not necessarily 
mean that the trial is adequately powered. Critical appraisal of the assumptions made based on realistic 
knowledge of the field is needed in each case – provided of course that the sample size calculation is fully 
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Figure 1. Figure showing the relationship between statistical power (1-β; y axis) and total number of 
patients included in a two-group parallel trial for five different minimal clinically important differences with 
Cohen’s d: 1.3, 1.0, 0.8, 0.5, and 0.3. All calculations are done assuming a pain response of 28.8 mm in 
VAS scale 24 hours after insertion for the control group, common standard deviations for the two groups, 
and α set at 5% for a t-test for independent samples. The pink dotted horizontal line denotes power of 
80%. 
 
